慢性腎臓病治療市場：治療別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

慢性腎臓病治療市場は2022年に320億米ドルと評価され、2023年から2032年にかけてCAGR 4%で成長し、2032年には479億米ドルに達すると推定されます。

慢性腎臓病（CKD）治療とは、腎臓障害とそれに関連する合併症の管理と進行抑制を目的とした様々な医療介入と戦略を指します。CKDは、腎臓が血液中の老廃物や余分な水分をろ過する機能を徐々に失っていく進行性の疾患です。CKD治療の目標には、腎機能の維持、症状のコントロール、合併症の予防または管理、CKD患者の全体的な生活の質の向上などが含まれます。

治療のアプローチには、生活習慣の改善（食生活の見直しや定期的な運動など）、血圧のコントロールや基礎疾患の管理のための薬物療法、貧血や骨疾患などの合併症への介入、進行期には透析や腎移植などの腎代替療法が含まれます。治療計画は、個々のCKDの病期、基礎疾患、併存疾患、全般的な健康状態に合わせて立てられます。CKD患者の転帰を最適化し、腎臓の健康を維持するためには、定期的なモニタリング、ヘルスケアプロバイダーとの緊密な連携、治療計画の遵守が不可欠です。

CKDの有病率の増加は、CKD治療市場の重要な促進要因です。CKDの世界の負担は、高齢化、糖尿病や高血圧などの危険因子の有病率の増加、認知度や診断の向上など、さまざまな要因によって着実に増加しています。例えば、人口の高齢化はCKD有病率増加の主な要因です。高齢化に伴い、CKD発症リスクは増加する傾向にあります。2022年の世界保健機関（WHO）によると、60歳以上の世界人口は2050年までに20億人に達すると予想されており、CKDを含む加齢関連疾患の有病率に大きな影響を与えます。

さらに、糖尿病や高血圧などの危険因子の罹患率の上昇が、CKDの流行に拍車をかけています。特に糖尿病はCKDの主要な原因です。2021年の国際糖尿病連合は、約5億3,700万人の成人が糖尿病を患っていると推定しており、この数は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測されています。このように、CKD発症リスクの高さに直結する症例が市場成長を牽引しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競合の激しさ
• 市場力学
  • 促進要因
    • 慢性腎臓病治療の技術的進歩
    • 慢性腎臓病（CKD）有病率の増加
  • 抑制要因
    • 慢性腎臓病治療の高コスト
  • 機会
    • 新興市場における成長機会
• COVID-19市場への影響分析

第4章 慢性腎臓病治療市場：治療別

• 概要
• 医薬品
• 透析療法

第5章 慢性腎臓病治療薬市場：エンドユーザー別

• 概要
• 病院
• 透析センター
• その他

第6章 慢性腎臓病治療市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ・中東・アフリカ
  • ブラジル
  • サウジアラビア
  • 南アフリカ
  • その他の地域

第7章 競合情勢

• イントロダクション
• 主要成功戦略
• 主要10社の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング、2022年

第8章 企業プロファイル

• AstraZeneca plc
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Baxter International Inc.
• Becton, Dickinson and Company
• B. Braun SE
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Fresenius SE and Co. KGaA

LIST OF TABLES

• TABLE 01. GLOBAL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 02. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DRUGS, BY REGION, 2022-2032 ($MILLION)
• TABLE 03. GLOBAL DRUGS CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 04. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS, BY REGION, 2022-2032 ($MILLION)
• TABLE 05. GLOBAL DIALYSIS CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
• TABLE 06. GLOBAL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 07. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR HOSPITAL, BY REGION, 2022-2032 ($MILLION)
• TABLE 08. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS CENTER, BY REGION, 2022-2032 ($MILLION)
• TABLE 09. CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 10. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
• TABLE 11. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 12. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 13. NORTH AMERICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 14. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 15. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 16. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 17. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 18. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 19. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 20. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 21. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 22. EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 23. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 24. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 25. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 26. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 27. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 28. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 29. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 30. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 31. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 32. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 33. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 34. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 35. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 36. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 37. ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 38. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 39. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 40. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 41. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 42. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 43. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 44. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 45. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 46. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 47. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 48. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 49. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 50. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 51. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 52. LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 53. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 54. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 55. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 56. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 57. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 58. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 59. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
• TABLE 60. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
• TABLE 61. ASTRAZENECA PLC: KEY EXECUTIVES
• TABLE 62. ASTRAZENECA PLC: COMPANY SNAPSHOT
• TABLE 63. ASTRAZENECA PLC: PRODUCT SEGMENTS
• TABLE 64. ASTRAZENECA PLC: PRODUCT PORTFOLIO
• TABLE 65. ASTRAZENECA PLC: KEY STRATERGIES
• TABLE 66. PFIZER INC.: KEY EXECUTIVES
• TABLE 67. PFIZER INC.: COMPANY SNAPSHOT
• TABLE 68. PFIZER INC.: PRODUCT SEGMENTS
• TABLE 69. PFIZER INC.: PRODUCT PORTFOLIO
• TABLE 70. JOHNSON & JOHNSON: KEY EXECUTIVES
• TABLE 71. JOHNSON & JOHNSON: COMPANY SNAPSHOT
• TABLE 72. JOHNSON & JOHNSON: PRODUCT SEGMENTS
• TABLE 73. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
• TABLE 74. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
• TABLE 75. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
• TABLE 76. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
• TABLE 77. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
• TABLE 78. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
• TABLE 79. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
• TABLE 80. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
• TABLE 81. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
• TABLE 82. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
• TABLE 83. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
• TABLE 84. BECTON, DICKINSON AND COMPANY: PRODUCT SEGMENTS
• TABLE 85. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
• TABLE 86. B. BRAUN SE: KEY EXECUTIVES
• TABLE 87. B. BRAUN SE: COMPANY SNAPSHOT
• TABLE 88. B. BRAUN SE: PRODUCT SEGMENTS
• TABLE 89. B. BRAUN SE: PRODUCT PORTFOLIO
• TABLE 90. B. BRAUN SE: KEY STRATERGIES
• TABLE 91. ABBVIE INC.: KEY EXECUTIVES
• TABLE 92. ABBVIE INC.: COMPANY SNAPSHOT
• TABLE 93. ABBVIE INC.: PRODUCT SEGMENTS
• TABLE 94. ABBVIE INC.: PRODUCT PORTFOLIO
• TABLE 95. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
• TABLE 96. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
• TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
• TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
• TABLE 99. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES
• TABLE 100. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
• TABLE 101. FRESENIUS SE AND CO. KGAA: PRODUCT SEGMENTS
• TABLE 102. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
• TABLE 103. FRESENIUS SE AND CO. KGAA: KEY STRATERGIES

LIST OF FIGURES

• FIGURE 01. CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032
• FIGURE 02. SEGMENTATION OF CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032
• FIGURE 03. TOP INVESTMENT POCKETS IN CHRONIC KIDNEY DISEASE TREATMENT MARKET (2023-2032)
• FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
• FIGURE 05. LOW BARGAINING POWER OF BUYERS
• FIGURE 06. LOW THREAT OF SUBSTITUTES
• FIGURE 07. LOW THREAT OF NEW ENTRANTS
• FIGURE 08. LOW INTENSITY OF RIVALRY
• FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCHRONIC KIDNEY DISEASE TREATMENT MARKET
• FIGURE 10. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT, 2022(%)
• FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DRUGS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 13. CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER, 2022(%)
• FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR HOSPITAL, BY COUNTRY 2022 AND 2032(%)
• FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR DIALYSIS CENTER, BY COUNTRY 2022 AND 2032(%)
• FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CHRONIC KIDNEY DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
• FIGURE 17. CHRONIC KIDNEY DISEASE TREATMENT MARKET BY REGION, 2022
• FIGURE 18. U.S. CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 19. CANADA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 20. MEXICO CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 21. GERMANY CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 22. FRANCE CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 23. UK CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 24. ITALY CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 25. SPAIN CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 26. REST OF EUROPE CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 27. JAPAN CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 28. CHINA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 29. AUSTRALIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 30. INDIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 31. SOUTH KOREA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 32. REST OF ASIA-PACIFIC CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 33. BRAZIL CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 34. SAUDI ARABIA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 35. SOUTH AFRICA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 36. REST OF LAMEA CHRONIC KIDNEY DISEASE TREATMENT MARKET, 2022-2032 ($MILLION)
• FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
• FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
• FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
• FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 41. COMPETITIVE DASHBOARD
• FIGURE 42. COMPETITIVE HEATMAP: CHRONIC KIDNEY DISEASE TREATMENT MARKET
• FIGURE 43. TOP PLAYER POSITIONING, 2022
• FIGURE 44. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
• FIGURE 45. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
• FIGURE 46. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)
• FIGURE 47. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 48. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 49. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 50. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
• FIGURE 51. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 52. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 55. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 56. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
• FIGURE 57. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 58. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 59. BECTON, DICKINSON AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 60. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 61. BECTON, DICKINSON AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 62. B. BRAUN SE: NET SALES, 2020-2022 ($MILLION)
• FIGURE 63. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 64. B. BRAUN SE: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 65. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 66. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
• FIGURE 67. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
• FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
• FIGURE 70. FRESENIUS SE AND CO. KGAA: NET SALES, 2019-2021 ($MILLION)
• FIGURE 71. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
• FIGURE 72. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY REGION, 2021 (%)

According to a new report published by Allied Market Research, titled, "Chronic kidney disease treatment Market," The chronic kidney disease treatment market was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

Chronic Kidney Disease (CKD) treatment refers to a range of medical interventions and strategies aimed at managing and slowing the progression of kidney damage and its associated complications. CKD is a progressive condition where the kidneys gradually lose their ability to filter waste products and excess fluids from the blood. The goals of CKD treatment include preserving kidney function, controlling symptoms, preventing or managing complications, and improving the overall quality of life for individuals with CKD.

Treatment approaches may include lifestyle modifications (such as dietary changes and regular physical activity), medications to control blood pressure and manage underlying conditions, interventions to address complications like anemia or bone disease, and in advanced stages, renal replacement therapies such as dialysis or kidney transplantation. The treatment plan is tailored to the individual's stage of CKD, underlying causes, comorbidities, and overall health status. Regular monitoring, close collaboration with healthcare providers, and adherence to the treatment plan are essential for optimizing outcomes and maintaining kidney health in individuals with CKD.

The increasing prevalence of CKD is a significant driver of the CKD treatment market. The global burden of CKD has been steadily rising due to various factors, including the aging population, the growing prevalence of risk factors such as diabetes and hypertension, and improved awareness and diagnosis. For instance, the aging population is a major contributing factor to the increasing prevalence of CKD. As people age, the risk of developing CKD tends to increase. According to the World Health Organization (WHO) in 2022, the global population aged 60 and above is expected to reach 2 billion by 2050, with a significant impact on the prevalence of age-related diseases, including CKD.

Furthermore, the rising incidence of risk factors like diabetes and hypertension has fueled the CKD epidemic. Diabetes, in particular, is a leading cause of CKD. The International Diabetes Federation in 2021, estimates that approximately 537 million adults were living with diabetes, and this number is projected to rise to 643 million by 2030 and 783 million by 2045. Thus, the prevailing cases, that directly translate to a higher risk of CKD development are anticipated to drive the market growth.

In addition, increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the chronic kidney disease treatment market.

However, factors that hinder the market growth include the high cost of treatment for chronic kidney disease. Further, limited access to healthcare and inadequate healthcare infrastructure in certain regions can hinder the timely diagnosis and management of CKD. Thus, the aforementioned factors negatively impact market growth.

Moreover, the rise in the number of approvals from government regulatory agencies is creating lucrative opportunities for the CKD treatment market. For instance, in September 2022, AstraZeneca, a global leading life science company, received approval in China for Forxiga, to reduce the risk of sustained estimated glomerular filtration rate ((eGFR)) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression with and without type-2 diabetes (T2D). In addition, the increase in investment in R&D activities increases the demand for efficient treatments, thereby providing lucrative opportunities for market growth.

The chronic kidney disease treatment market is segmented on the basis of treatment, end user, and region. On the basis of treatment, the market is classified into drugs and dialysis. The drugs is further categories into ACE Inhibitors, Erythropoietic Stimulating agents, Diuretics, and Other (phosphate binder, beta blockers, calcium channel blockers) and the dialiysis is further categorised into equipment and consumables. As per end user the market is segmented into Hospitals , Dialysis Centers and others (homecare and research and academic institutes). Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global chronic kidney disease treatment market are AstraZeneca plc, Pfizer Inc. Johnson & Johnson, F. Hoffmann-La Roche Ltd., Baxter International Inc., Becton, Dickinson and Company, B. Braun SE, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Fresenius SE and Co. KGaA. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

• Hospital
• Dialysis Center
• Others

By Treatment

• Drugs
  • Type
  • Erythropoietic Stimulating agents
  • Ace Inhibitors
  • Diuretics
  • Others
• Dialysis
  • Type
  • Equipment
  • Consumables

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Pfizer Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc
• B. Braun SE
• AbbVie Inc.
• Fresenius SE and Co. KGaA
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Baxter International Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Bargaining power of suppliers
  • 3.3.2. Bargaining power of buyers
  • 3.3.3. Threat of substitutes
  • 3.3.4. Threat of new entrants
  • 3.3.5. Intensity of rivalry
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Technological advancement in chronic kidney disease treatment
    • 3.4.1.2. Increase in prevalence of chronic kidney disease (CKD)

• 3.4.2. Restraints
  • 3.4.2.1. High cost of CKD treatment

• 3.4.3. Opportunities
  • 3.4.3.1. Growth opportunities in emerging markets

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY TREATMENT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Drugs
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Drugs Chronic kidney disease treatment Market by Type
• 4.3. Dialysis
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Dialysis Chronic kidney disease treatment Market by Type

CHAPTER 5: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY END USER

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Hospital
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Dialysis Center
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: CHRONIC KIDNEY DISEASE TREATMENT MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key trends and opportunities
  • 6.2.2. Market size and forecast, by Treatment
  • 6.2.3. Market size and forecast, by End User
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Key market trends, growth factors and opportunities
    • 6.2.4.1.2. Market size and forecast, by Treatment
    • 6.2.4.1.3. Market size and forecast, by End User
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Key market trends, growth factors and opportunities
    • 6.2.4.2.2. Market size and forecast, by Treatment
    • 6.2.4.2.3. Market size and forecast, by End User
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Key market trends, growth factors and opportunities
    • 6.2.4.3.2. Market size and forecast, by Treatment
    • 6.2.4.3.3. Market size and forecast, by End User
• 6.3. Europe
  • 6.3.1. Key trends and opportunities
  • 6.3.2. Market size and forecast, by Treatment
  • 6.3.3. Market size and forecast, by End User
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Key market trends, growth factors and opportunities
    • 6.3.4.1.2. Market size and forecast, by Treatment
    • 6.3.4.1.3. Market size and forecast, by End User
    • 6.3.4.2. France
    • 6.3.4.2.1. Key market trends, growth factors and opportunities
    • 6.3.4.2.2. Market size and forecast, by Treatment
    • 6.3.4.2.3. Market size and forecast, by End User
    • 6.3.4.3. UK
    • 6.3.4.3.1. Key market trends, growth factors and opportunities
    • 6.3.4.3.2. Market size and forecast, by Treatment
    • 6.3.4.3.3. Market size and forecast, by End User
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Key market trends, growth factors and opportunities
    • 6.3.4.4.2. Market size and forecast, by Treatment
    • 6.3.4.4.3. Market size and forecast, by End User
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Key market trends, growth factors and opportunities
    • 6.3.4.5.2. Market size and forecast, by Treatment
    • 6.3.4.5.3. Market size and forecast, by End User
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Key market trends, growth factors and opportunities
    • 6.3.4.6.2. Market size and forecast, by Treatment
    • 6.3.4.6.3. Market size and forecast, by End User
• 6.4. Asia-Pacific
  • 6.4.1. Key trends and opportunities
  • 6.4.2. Market size and forecast, by Treatment
  • 6.4.3. Market size and forecast, by End User
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Key market trends, growth factors and opportunities
    • 6.4.4.1.2. Market size and forecast, by Treatment
    • 6.4.4.1.3. Market size and forecast, by End User
    • 6.4.4.2. China
    • 6.4.4.2.1. Key market trends, growth factors and opportunities
    • 6.4.4.2.2. Market size and forecast, by Treatment
    • 6.4.4.2.3. Market size and forecast, by End User
    • 6.4.4.3. Australia
    • 6.4.4.3.1. Key market trends, growth factors and opportunities
    • 6.4.4.3.2. Market size and forecast, by Treatment
    • 6.4.4.3.3. Market size and forecast, by End User
    • 6.4.4.4. India
    • 6.4.4.4.1. Key market trends, growth factors and opportunities
    • 6.4.4.4.2. Market size and forecast, by Treatment
    • 6.4.4.4.3. Market size and forecast, by End User
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Key market trends, growth factors and opportunities
    • 6.4.4.5.2. Market size and forecast, by Treatment
    • 6.4.4.5.3. Market size and forecast, by End User
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Key market trends, growth factors and opportunities
    • 6.4.4.6.2. Market size and forecast, by Treatment
    • 6.4.4.6.3. Market size and forecast, by End User
• 6.5. LAMEA
  • 6.5.1. Key trends and opportunities
  • 6.5.2. Market size and forecast, by Treatment
  • 6.5.3. Market size and forecast, by End User
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Key market trends, growth factors and opportunities
    • 6.5.4.1.2. Market size and forecast, by Treatment
    • 6.5.4.1.3. Market size and forecast, by End User
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Key market trends, growth factors and opportunities
    • 6.5.4.2.2. Market size and forecast, by Treatment
    • 6.5.4.2.3. Market size and forecast, by End User
    • 6.5.4.3. South Africa
    • 6.5.4.3.1. Key market trends, growth factors and opportunities
    • 6.5.4.3.2. Market size and forecast, by Treatment
    • 6.5.4.3.3. Market size and forecast, by End User
    • 6.5.4.4. Rest of LAMEA
    • 6.5.4.4.1. Key market trends, growth factors and opportunities
    • 6.5.4.4.2. Market size and forecast, by Treatment
    • 6.5.4.4.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. AstraZeneca plc
  • 8.1.1. Company overview
  • 8.1.2. Key Executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. Pfizer Inc.
  • 8.2.1. Company overview
  • 8.2.2. Key Executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
• 8.3. Johnson & Johnson
  • 8.3.1. Company overview
  • 8.3.2. Key Executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
• 8.4. F. Hoffmann-La Roche Ltd.
  • 8.4.1. Company overview
  • 8.4.2. Key Executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
• 8.5. Baxter International Inc.
  • 8.5.1. Company overview
  • 8.5.2. Key Executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
• 8.6. Becton, Dickinson and Company
  • 8.6.1. Company overview
  • 8.6.2. Key Executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
• 8.7. B. Braun SE
  • 8.7.1. Company overview
  • 8.7.2. Key Executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. AbbVie Inc.
  • 8.8.1. Company overview
  • 8.8.2. Key Executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
• 8.9. Teva Pharmaceutical Industries Ltd.
  • 8.9.1. Company overview
  • 8.9.2. Key Executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
• 8.10. Fresenius SE and Co. KGaA
  • 8.10.1. Company overview
  • 8.10.2. Key Executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance
  • 8.10.7. Key strategic moves and developments